Search clinical trials for: Flavivirus naïve

Total 1066 results

R-Pharm
Almedis; Scientific Center EFiS; ChromSystemsLab

Completed

Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1

Chronic Hepatitis c Genotype 1

Russian Federation
Atea Pharmaceuticals, Inc.

Completed

Study of AT-752 in Healthy Subjects

Dengue

Australia
ViiV Healthcare
GlaxoSmithKline

Completed

ING200336, Pharmacokinetic and Safety Study in Pregnant Women With Human Immuno Virus Infection

HIV Infections | Arthralgia | Infection, Human Immunodeficiency Virus

Spain, Russian Federation
Glaukos Corporation

Completed

Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost

Open-angle Glaucoma

Armenia
PharmaEssentia

Completed

The Pharmacokinetics of P1101 + Ribavirin in Interferon Treatment-Naïve Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection

Hepatitis C, Chronic

Taiwan
AbbVie
Genentech, Inc.

Completed

A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia

AML | Acute Myelogenous Leukemia

United States, Australia, Germany, Italy
Children's National Research Institute
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Enrolling by invitation

Neurodevelopmental Outcomes in ZIKV-Exposed Children

Child Development | Congenital Zika Syndrome | Zika Virus | Congenital Infection

United States, Colombia
Takeda

Completed

Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Co-administered With an Hepatitis A Virus Vaccine

Healthy Volunteers

United Kingdom
Themis Bioscience GmbH

Completed

Zika-Vaccine Dose Finding Study Regarding Safety, Immunogenicity and Tolerability (V186-001)

Zika Virus

Austria
AbbVie

Completed

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-II)

Chronic Hepatitis C Virus (HCV) Infection Genotype 1

United States
Sanaria Inc.
Fred Hutchinson Cancer Center

Completed

Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults

Malaria

United States
University of Heidelberg Medical Center
London School of Hygiene and Tropical Medicine; Institut National de la Santé... and other collaborators

Completed

ZIKAlliance Pregnant Women Cohort (ZIKAlliancePW)

Pregnancy Related | Zika Virus

Brazil, Bolivia, Colombia, Cuba, Guadeloupe, Mexico, Venezuela
University of Heidelberg Medical Center

Completed

ZIKAlliance Children Cohort (ZIKAllianceCH) (ZIKAllianceCH)

Zika Virus

Brazil, Bolivia, Colombia, Cuba, Guadeloupe, Mexico, Venezuela
University of Heidelberg Medical Center
University of Sao Paulo

Withdrawn

ZIKAlliance Natural History Study (ZIKAllianceNH)

Zika Virus Infection | Zika Virus

Brazil
Institut National de la Santé Et de la Recherche...

Completed

Zika Virus Infection's Pregnancy Consequences in French Department of America (ZIKA-DFA-FE)

Incidence of ZIKV Infection on Fetus During the Pregnancy

France
Sanofi Pasteur, a Sanofi Company

Completed

Zika Case Definition and Surveillance Study

Zika Virus Disease

Colombia, Honduras, Mexico, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Postmarketing Surveillance Study for IMOJEV® in Republic of Korea

Japanese Encephalitis

Korea, Republic of
Sanofi

Completed

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulins in Insulin Naïve Patients Initiating Insulin (Reach-Control)

Diabetes Mellitus, Type 2

Germany, Spain, Brazil, France, Ireland, Romania, United Kingdom
Sanofi

Completed

Twelve -Month Study Observing How Insulin-naïve Patients With Type 2 Diabetes Mellitus Manage Diabetes Using Toujeo® After Oral Antidiabetic Drug Failure, the Side Effect of Toujeo®, and The Cost. (ATOS)

Diabetes

Peru, Ukraine, Colombia, Egypt, India, Indonesia, Israel, Jordan, Kuwait, Lebanon, Mexico, Philippines, Russian Federation, Saudi Arabia, Singapore, Taiwan, Thailand, United Arab Emirates
Sanofi Pasteur, a Sanofi Company

Completed

Association of Host Genetics With Vaccine Efficacy and Study of Immune Correlates of Risk From a Tetravalent Dengue Vaccine

Dengue Fever | Dengue Haemorrhagic Fever

Thailand
Sanofi Pasteur, a Sanofi Company

Completed

Dose-ranging Study of an Investigational Yellow Fever Candidate Vaccine in Adults (VYF01)

Yellow Fever (Healthy Volunteers)

United States
Pedro Cahn
ViiV Healthcare

Withdrawn

Dolutegravir-Lamivudine as Dual Therapy in naïve HIV-Infected Patients With Documented M184V Mutation:A Pilot Study (PADDLE184V)

HIV-1 Infection

Argentina
Mount Sinai Hospital, Canada

Completed

A Comparison of Post-Operative Analgesia Requirements In Recreational Cannabis Users Versus Cannabis Naïve Inflammatory Bowel Disease Patients

Cannabis Use, Opioid Consumption

Canada
Universidad de Antioquia
United States Agency for International Development (USAID); Bill and Melinda... and other collaborators

Completed

Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia (WMP-COL)

Dengue | Zika Virus Infection | Chikungunya Virus Infection

Colombia
Sanofi Pasteur, a Sanofi Company

Completed

Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects

Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue Disease

Vietnam
Sanofi Pasteur, a Sanofi Company

Completed

Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years

Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue Diseases

Peru
Sanofi Pasteur, a Sanofi Company

Completed

Efficacy and Safety of Dengue Vaccine in Healthy Children

Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue Diseases

Thailand
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India

Dengue | Dengue Fever | Dengue Hemorrhagic Fever

India
SingHealth Polyclinics

Completed

Effects of a Serious Game on Knowledge, Attitude and Practice in Vector Control and Dengue Prevention Among Adults in Primary Care

Dengue

Singapore
Sanofi Pasteur, a Sanofi Company

Completed

Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study

Dengue | Dengue Fever | Dengue Hemorrhagic Fever

Thailand
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South Korea

Japanese Encephalitis

Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Completed

Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV

Japanese Encephalitis | Varicella

Philippines
Sanofi Pasteur, a Sanofi Company
National Institute of Hygiene and Epidemiology, Vietnam

Completed

Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy Subjects

Japanese Encephalitis

Vietnam
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil®

Dengue Fever | Dengue Hemorrhagic Fever | Human Papillomavirus Disease

Malaysia
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix®

Dengue Fever | Dengue Hemorrhagic Fever | Human Papillomavirus Disease

Mexico
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers

Dengue | Dengue Hemorrhagic Fever

Mexico
Sanofi Pasteur, a Sanofi Company

Completed

Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers

Yellow Fever | Dengue | Dengue Hemorrhagic Fever

Peru, Colombia
Sanofi Pasteur, a Sanofi Company

Terminated

Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects

Dengue Fever | Dengue Hemorrhagic Fever

Philippines
Sanofi

Completed

Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia

Dengue Fever | Dengue Hemorrhagic Fever

Malaysia
Sanofi Pasteur, a Sanofi Company

Completed

Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine

Yellow Fever | Dengue | Dengue Fever | Dengue Hemorrhagic Fever

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age

Dengue Fever | Dengue Hemorrhagic Fever

Colombia, Philippines
Sanofi Pasteur, a Sanofi Company
United States Department of Defense

Completed

Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine

Dengue | Dengue Fever | Dengue Hemorrhagic Fever

United States
Tychan Pte Ltd.
Duke-NUS Graduate Medical School; Singapore Clinical Research Institute

Withdrawn

Safety and Tolerability of an Antibody Against Zika Virus (Tyzivumab) in ZIKV Infected Patients

Treatment of Acute Zika Virus Infection

Singapore
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule

Dengue Fever | Dengue Hemorrhagic Fever

Brazil, Colombia, Honduras, Mexico, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America

Dengue | Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus

Puerto Rico, Colombia, Mexico, Honduras
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule

Dengue Fever | Dengue Hemorrhagic Fever

Singapore
Sanofi Pasteur, a Sanofi Company

Completed

Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore

Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue Diseases

Singapore
Brugmann University Hospital

Completed

Analysis of naïve Patients With Age-related Macular Degeneration Neovascular Type and Treated With Ranibizumab (Lucentis®) in Treat-and-extend at the CHU Brugmann.

Macular Degeneration

Belgium
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia

Dengue | Dengue Fever | Dengue Hemorrhagic Fever

Indonesia, Philippines, Malaysia, Thailand, Vietnam
University Hospital Center of Martinique
University Hospital of Guadeloupe

Terminated

Estimated Cumulative Incidence of Zika Infection at the End of the First Epidemic in the French West Indies in a Sample of Patients Followed for HIV Infection. (ZIKAVIH)

HIV Infections | Zika Virus Infection

Guadeloupe, Martinique

Search clinical trials for: Flavivirus naïve

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Greece

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations